Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.

PHASE2RecruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

August 14, 2023

Primary Completion Date

August 14, 2025

Study Completion Date

November 30, 2025

Conditions
Hepatic CarcinomaHepatic Metastasis
Interventions
DRUG

Octreotide

"A loading dose of 100 mcgr of octreotide will be administered in the intervention group, diluted in 100 ml of SSF to be passed in 30 minutes.~Subsequently, it will be administered in continuous perfusion at 25 mcgr/h in the intervention group.~The drug can be administered through a peripheral or central venous line at the choice of the anesthesiologist, since the drug has a density that allows its administration by both routes."

OTHER

Placebo

In the case of the control group, 100 ml of SSF will be administered to be passed in half an hour and then an perfusion of SSF.

Trial Locations (1)

31007

RECRUITING

Clinica Universidad de Navarra, Pamplona

All Listed Sponsors
lead

Clinica Universidad de Navarra, Universidad de Navarra

OTHER